A newly published cache of CRLs includes six novel oncology drugs.
ApexOnco Front Page
Recent articles
The deal for ISB 2001 is worth $700m up front.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
But sasanlimab's use looks set to remain narrow.
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
Skyscraper-07 fails, while a Poseida-originated Car-T is also scrapped.
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
